Literature DB >> 29679904

Tanshinone IIA protects murine chondrogenic ATDC5 cells from lipopolysaccharide-induced inflammatory injury by down-regulating microRNA-203a.

Luan Luan1, Zhiyuan Liang2.   

Abstract

BACKGROUND: Osteoarthritis is the most common bone-joint disease in middle and older people all over the world. Tanshinone IIA (Tan IIA) is the main lipophilic diterpenoid isolated from the root of Salvia miltiorrhiza Bunge (Lamiaceae). This study analyzed the protective effects of Tan IIA on lipopolysaccharide (LPS)-induced murine chondrogenic ATDC5 cell inflammatory injury model.
METHODS: Cell viability was assessed using cell counting kit-8 (CCK-8) assay. Cell apoptosis was detected using Annexin V-FITC/PI staining. Enzyme-linked immunosorbent assay (ELISA) was conducted to measure the concentrations of interleukin 6 (IL-6), IL-8 and tumor necrosis factor α (TNF-α) in the culture supernatant of ATDC5 cells. qRT-PCR was performed to determine the expression of IL-6, IL-8, TNF-α and microRNA-203a (miR-203a) in ATDC5 cells. Cell transfection was used to enhance the expression of miR-203a. Protein expression of key factors involved in apoptosis, pro-inflammatory reaction, Janus kinase/signal transducers and activators of transcription (JAK/STAT) and c-Jun-N-terminal kinase (JNK) pathways were evaluated using western blotting.
RESULTS: LPS significantly induced ATDC5 cell inflammatory injury, as evidenced by the loss of cell viability, enhancement of cell apoptosis and increases of pro-inflammatory factors expression. Tan IIA obviously alleviated LPS-induced ATDC5 cell inflammatory injury and down-regulated the expression of miR-203a. Overexpression of miR-203a obviously promoted ATDC5 cell inflammatory injury and remarkably reversed the protective effects of Tan IIA on LPS-induced ATDC5 cell inflammatory injury by influencing JAK/STAT and JNK pathways.
CONCLUSION: Our research verified that Tan IIA protected ATDC5 cells from LPS-induced inflammatory injury by down-regulating miR-203a and suppressing JAK/STAT and JNK pathways.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  JAK/STAT signaling pathway; JNK signaling pathway; Lipopolysaccharide; MicroRNA-203a; Osteoarthritis; Tanshinone IIA

Mesh:

Substances:

Year:  2018        PMID: 29679904     DOI: 10.1016/j.biopha.2018.04.051

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   7.419


  5 in total

1.  TanshinoneIIA Alleviates Inflammatory Response and Directs Macrophage Polarization in Lipopolysaccharide-Stimulated RAW264.7 Cells.

Authors:  Shan Gao; Yili Wang; Dan Li; Yuying Guo; Meifeng Zhu; Shixin Xu; Jingyuan Mao; Guanwei Fan
Journal:  Inflammation       Date:  2019-02       Impact factor: 4.092

2.  Tanshinone I Inhibits IL-1β-Induced Apoptosis, Inflammation And Extracellular Matrix Degradation In Chondrocytes CHON-001 Cells And Attenuates Murine Osteoarthritis.

Authors:  Xipeng Wang; Jianbo Fan; Xiaomin Ding; Yuyu Sun; Zhiming Cui; Wei Liu
Journal:  Drug Des Devel Ther       Date:  2019-10-15       Impact factor: 4.162

3.  Investigating the protective effect of tanshinone IIA against chondrocyte dedifferentiation: a combined molecular biology and network pharmacology approach.

Authors:  Yushen Zhang; Liguo Sun; Xincheng Liu; Dongze Zhu; Jingyi Dang; Yingsen Xue; Hongbin Fan
Journal:  Ann Transl Med       Date:  2021-02

4.  Down-regulation of microRNA-203a suppresses IL-1β-induced inflammation and cartilage degradation in human chondrocytes through Smad3 signaling.

Authors:  Yongbo An; Guang Wan; Jingang Tao; Mingxing Cui; Qinglan Zhou; Wengen Hou
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

5.  Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro.

Authors:  Bo Ding; Chengheng Lin; Qian Liu; Yingying He; John Bosco Ruganzu; Hui Jin; Xiaoqian Peng; Shengfeng Ji; Yanbing Ma; Weina Yang
Journal:  J Neuroinflammation       Date:  2020-10-14       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.